NCT05584800

Study of ZGGS18 in Patients With Advanced Solid Tumors

A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 222 (estimated)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	ZGGS18 for Injection	0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
BIOLOGICAL	ZGGS18 for Injection	Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.

Timeline

• Start date: 2022-11-15
• Primary completion: 2026-11-01
• Completion: 2026-11-01
• First posted: 2022-10-18
• Last updated: 2026-01-05

Locations

1 site across 1 country: China